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1. Introduction
The definition of anemia is controversial. The WHO defines anemia as hemoglobin (Hb)<13
g/dL for men and <12 g/dL for women [1]. The National Kidney Foundation's Kidney Dis‐
ease Outcomes Quality Initiative, which is the criteria used for Medicare reimbursement, de‐
fines anemia in adult men and postmenopausal women as Hb<12 g/dL, or <11 g/dL in a
premenopausal woman [2]. Anemia represents a significant problem to deal with in patients
with chronic kidney disease (CKD) on hemodialysis (HD). Renal anemia is typically an iso‐
lated normochromic, normocytic anemia with no leukopenia or thrombocytopenia [3]. This
is a frequent complication and contributes considerably to reduced quality of life (QoL) [4-6]
of patients with CKD. It has also been associated with a number of adverse clinical out‐
comes, increased morbidity and mortality [5, 7-13]. In general, there is a progressive increase
in the incidence and severity of anemia with declining renal function. The reported preva‐
lence of anemia by CKD stage varies significantly and depends, to a large extent, on the def‐
inition of anemia and whether study participants selected from the general population, are
at a high risk for CKD. Data from the National Health and Nutrition Examination Survey
(NHANES) showed that the distribution of Hb levels starts to fall at an estimated glomeru‐
lar filtration rate (eGFR) of less than 75 ml/min per 1.73 m2 in men and 45 ml/min per 1.73
m2 in women [14]. Among patients under regular care and known to have CKD, the preva‐
lence of anemia was found to be much greater, with mean Hb levels of 12.8 ± 1.5 g/dl (CKD
stages 1 and 2), 12.4 ± 1.6 g/dl (CKD stage 3), 12.0 ± 1.6 g/dl (CKD stage4), and 10.9 ± 1.6 g/dl
(CKD stage 5) [15]. Although renal anemia is independent of the etiology of kidney disease,
there are two important exceptions. Renal anemia in diabetic patients develops more fre‐
quently, at earlier stages of CKD, and more severely at a given level of renal impairment
[16-18]. In patients with polycystic kidney disease, Hb is higher than in other patients with
similar degrees of renal failure, and polycythemia may occasionally develop [19]. Many pa‐
tients not yet on dialysis still receive no specific treatment for their anemia. In contrast, in
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patients on dialysis,, average Hb values have steadily increased during the past 15 years,
following the advent of erythropoietin (EPO) and the development of clinical practice guide‐
lines for anemia management [16, 17]. Anemia contributes to significant healthcare costs as‐
sociated with CKD [20]. The average Hb value, however, varies considerably between
countries, reflecting variability in practice patterns [21]. Before the availability of recombi‐
nant human erythropoietin (rhuEPO, or epoetin), patients on dialysis frequently required
blood transfusions, exposing them to the risks of iron overload, transmission of viral hepati‐
tis, and sensitization, which reduced the chances of successful transplantation. Anemia in
CKD patients except from the lack of EPO [22, 23], is a multifactor process. Shorter lifespan
of red blood cells, iron and vitamin deficiency due to dietary restrictions, and rarely bleed‐
ing that accompanies uremia seem to be other important factors [24, 25]. Adequate dialysis
can contribute to anemia correction through many mechanisms, including the removal of
molecules that may inhibit erythropoiesis using high-flux dialyzers [26-30]. It also seems
that residual renal function is important in dialysis patients and its decline also contributes
significantly to anemia, inflammation, and malnutrition in patients on dialysis [31, 32]. It is
also affected by the underlying disease, co morbid conditions, malignancy, infection, heart
failure, as mentioned above, the environment and several other factors (therapeutic treat‐
ment with angiotensin-converting enzyme(ACE) inhibitors, [33-37] increased PTH, [38-43]
osteodystrophy [44, 45]) that differ among patients. Thus, anemia management in these pa‐
tients needs an individualized approach. Each patient should be treated according to an Hb
target with the lowest effective Erythropoiesis Stimulating Agents (ESA) dose, while avoid‐
ing large fluctuations in Hb levels or prolonged periods outside the target. This strategy
may necessitate changes to the ESA dose, dosing frequency and iron supplementation over
the course of a patient's treatment, and proactive management of conditions that can affect
ESA responsiveness. While all ESAs effectively increase Hb levels, differences with respect
to route of administration, pharmacokinetics, and dosing frequency and efficiency should be
considered to maximize the benefits of ESA treatment for the individual patient [46]. Substi‐
tution of the subcutaneous route of administration for the intravenous route for epoetin-alfa
can reduce drug acquisition and costs, the two largest components of healthcare costs in
CKD patients [20]. Hence, treating anemia in CKD patients on HD seems to be very complex
and has to be managed step by step correcting all the factors that affect this process.
2. Diagnostic approach of anemia in hemodialysis patients
The diagnosis of anemia and the assessment of its severity are best made by measuring
the Hb concentration rather than the hematocrit. Hb is a stable analyte measured directly
in  a  standardized  fashion,  whereas  the  hematocrit  is  relatively  unstable,  indirectly  de‐
rived by  automatic  analyzers,  and lacking  of  standardization.  Within-run and between-
run coefficients of variation in automated analyzer measurements of Hb are one half and
one third those for hematocrit, respectively [16]. There is considerable variability in the Hb
threshold used to define anemia in CKD patients. According to the definition in the Kid‐
ney  Disease  Outcomes  Quality  Initiative  (KDOQI)  guidelines,  anemia  should  be  diag‐
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nosed at Hb concentrations of less than 13.5 g/dl in adult men and less than 12.0 g/dl in
adult  women [16].These  values  represent  the  mean  Hb concentration  of  the  lowest  5th
percentile of the sex-specific general adult population. In children, age-dependent differen‐
ces in the normal values have to be taken into account. Normal Hb values are increased
in high-altitude residents [16]. The end of the short interdialytic period is the most appro‐
priate timing for anemia assessment [47]. Although renal anemia is typically normochro‐
mic and normocytic, [48, 49] deficiency of vitamin B12 or folic acid may lead to macrocytosis,
whereas iron deficiency or inherited disorders of Hb formation (such as thalassemia) may
produce microcytosis. Macrocytosis with leucopenia or thrombocytopenia suggests a gen‐
eralized disorder of  hematopoiesis  caused by toxins,  nutritional  deficit,  or  myelodyspla‐
sia. Hypochromia probably reflects iron-deficient erythropoiesis. An absolute reticulocyte
count, which normally ranges between 40,000 and 50,000 cells/μl of blood, is a useful mark‐
er of  erythropoietic  activity.  Iron status tests should be performed to assess the level  of
iron in tissue stores or the adequacy of  iron supply for erythropoiesis.  Although serum
ferritin is so far the only available marker of storage iron, several tests reflect the adequa‐
cy of iron for erythropoiesis, including transferrin saturation, MCV, and MCHC; the per‐
centage of  hypochromic red blood cells  (PHRC);  and the content  of  Hb in reticulocytes
(CHr) [50].  Storage time of  the blood sample may elevate PHRC, MCV and MCHC are
below the normal range only after long-standing iron deficiency. It is important to identi‐
fy anemia in CKD patients because it may signify nutritional deficits, systemic illness, or
other conditions that  warrant  attention,  and even at  modest  degrees,  anemia reflects  an
independent risk factor for hospitalization, cardiovascular disease, and mortality [16, 51].
Drug therapy such as  ACE inhibitors  may reduce Hb levels  by:  firstly,  direct  effects  of
angiotensin II on erythroid progenitor cells, [52] secondly, accumulation of N-acetyl-seryl-
lysyl-proline (Ac-SDKP), an endogenous inhibitor of erythropoiesis, [53] and thirdly, reduc‐
tion  of  endogenous  EPO  production,  potentially  due  to  the  hemodynamic  effects  of
angiotensin II  inhibition [54].  Myelosuppressive effects of immunosuppressants may fur‐
ther contribute to anemia [55].The measurement of serum EPO concentrations is usually
not helpful in the diagnosis of renal anemia because there is relative rather than absolute
deficiency,  with  a  wide  range of  EPO concentrations  for  a  given Hb concentration that
extends far beyond the normal range of EPO levels on healthy, non-anemic individuals.
Abnormalities of other laboratory parameters should be investigated, such as a low MCV
or  MCHC (may indicate  an  underlying  hemoglobinopathy),  a  high  MCV (may indicate
vitamin  B12  or  folic  acid  deficiency),  or  an  abnormal  leukocyte  or  platelet  count  (may
suggest a primary bone marrow problem, such as myeloma or myelodysplastic syndrome).
3. Clinical manifestations
Due to the fact that anemia reduces tissue oxygenation, it is associated with widespread or‐
gan dysfunction and hence an extremely varied clinical picture. In mild anemia there may
be no symptoms or simply increased fatigue and a slight pallor. As anemia becomes more
marked the symptoms and signs gradually appear. Pallor is best discerned in the mucous
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membranes; the nailbeds and palmar creases, although often said to be useful sites for de‐
tecting anemia, are relatively insensitive for this purpose. Cardiorespiratory symptoms and
signs include dyspnea, tachycardia, palpitations, angina or claudication, night cramps, in‐
creased arterial pulsation, capillary pulsation, a variety of cardiac bruits, reversible cardiac
enlargement. Neuromuscular involvement is reflected by headache, vertigo, light-headed‐
ness, faintness, tinnitus, roaring in the ears, cramps, increased cold sensitivity. Acute anemia
may occasionally give rise to papilledema. Gastrointestinal symptoms include loss of appe‐
tite, nausea, constipation, and diarrhea. Genitourinary involvement causes menstrual irreg‐
ularities, urinary frequency, and loss of libido. There may also be a low-grade fever. In the
elderly, to whom associated degenerative arterial disease is common, anemia may be mani‐
fested with the onset of cardiac failure. Alternatively, previously undiagnosed coronary nar‐
rowing may be unmasked by the onset of angina [56].
In the early clinical trials of EPO performed in the late 1980s, the mean baseline Hb concen‐
tration was about 6 to 7 g/dl, and this progressively increased to about 11 or 12g/dl after
treatment. Patients subjectively felt much better, with reduced fatigue, increased energy lev‐
els, and enhanced physical capacity, and there were also objective improvements in cardior‐
espiratory function [57]. Thus, it is now clear that many of the symptoms previously
attributed to the “uremic syndrome” are indeed due to the anemia associated with CKD. Al‐
though the avoidance of blood transfusions and improvement in quality of life are obvious
early changes, there are also possible effects on the cardiovascular system. The physiologic
consequences of long-standing anemia are an increase in cardiac output and a reduction in
peripheral vascular resistance. Anemia is a risk factor for the development of left ventricular
hypertrophy in CKD patients and exacerbate left ventricular dilation. Sustained correction
of anemia in CKD patients results in a reversal of most of these cardiovascular abnormali‐
ties, with the notable exception of left ventricular dilation. Once the left ventricle is stretched
beyond the limits of its elasticity, correction of anemia cannot reverse this [58]. It may, how‐
ever, prevent the development of LV dilation, and this leads to improved quality of life [59].
Anemia correction may improve QoL, [60, 61] cognitive function, sleep patterns, nutrition,
sexual function, menstrual regularity, immune responsiveness, and platelet function [62-66].
4. Therapeutic approach
As mentioned above, renal anemia is a multifactor process and its treatment has to focus on
a step by step correction of all factors which are involved in this process [67]. First of all, iron
deficiency has to be treated before adding more expensive therapies such as EPO therapy.
4.1. Iron deficiency
Iron is an essential ingredient for heme synthesis, and adequate amounts of this mineral are
required for the manufacture of new red cells. Thus, under enhanced erythropoietic stimula‐
tion, greater amounts of iron are used, and many CKD patients have inadequate amounts of
available iron to satisfy the increased demands of the bone marrow [68]. Patients with CKD,
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on HD treatments, may lose up to 3gr of iron each year because of frequent blood losses, so
they are at particularly high risk of iron store depletion with subsequent iron deficiency ane‐
mia [17]. Even before the introduction of ESA therapy, many CKD patients were in negative
iron balance as a result of poor dietary intake, poor appetite, and increased iron losses due
to occult and overt blood losses. Losses on HD patients are up to 5 or 6 mg a day, compared
with 1 mg on healthy individuals, and this may exceed the absorption capacity of the gastro‐
intestinal tract, particularly when there is any underlying inflammation. Iron deficiency can
be defined as absolute or functional [17, 68, 69]. Absolute iron deficiency develops as the
body's iron stores become depleted to such a low level that not enough iron is available for
the production of Hb [70, 71]. This is usually indicated by a decline in serum ferritin levels
to ~<15 μg/l in patients with normal kidney function, [70, 71] or <12 ng/mL [72] according to
other studies and TSAT levels below 16% [73]. Absolute iron deficiency in CKD patients has
been defined as serum ferritin levels <100 ng/mL and TSAT levels <20%. The functional iron
deficiency describes the state when iron cannot be mobilized from stores (despite an ade‐
quate dietary supply) to meet the demand for erythropoiesis [70]. Serum ferritin levels can
appear normal (200–500 μg/l) or increased in chronic inflammatory disorders, [70] while lev‐
els of transferrin saturation (TSAT), which is serum iron divided by total iron-binding ca‐
pacity, [68] will be low (typically <20%), indicating limited transport of iron to the erythron
for erythropoiesis [70, 74, 75] and increased hypochromic red cells (>10%). The distinction
between absolute and functional iron deficiency is crucial to understanding what constitutes
adequate TSAT and serum ferritin levels on Epoetin-treated patients. The iron deficit limits
the effectiveness of EPO therapy, and, to optimize the treatment, patients must receive an
oral or intravenous (IV) iron supplement [76-78]. Thus, higher doses of ESAs may worsen
iron depletion and lead to an increased platelet count (thrombocytosis), ESA hyporespon‐
siveness, and hemoglobin variability. Hence, ESA therapy requires concurrent iron supple‐
mentation [17, 79]. On the other hand, serum ferritin <200 ng/mL suggests iron deficiency in
CKD patients, ferritin levels between 200 and 1,200 ng/mL may be related to inflammation,
latent infections, malignancies, or liver disease. In part, this is due to the fact that, in addi‐
tion to reflecting body iron stores, serum ferritin is also an acute phase reactant. As such, it
can increase in the setting of either acute or chronic inflammation. Available data demon‐
strate that the lower the TSAT and the serum ferritin, the higher the likelihood that a patient
is iron deficient, and the higher the TSAT and the serum ferritin, the lower the likelihood
that a patient is iron deficient [77, 80]. A serum ferritin concentration of 100-500 ng/mL is the
target during oral and intravenous (i.v.) iron therapy for pre-dialysis and peritoneal dialysis
patients, but use of the i.v. route of administration and a target serum ferritin concentration
of 200-500 ng/mL is recommended for HD patients by NKF [81]. Due to the fact that paren‐
teral iron administration has potential risks that are immediate (eg, toxic effects and anaphy‐
lactic reactions) and long-term (e.g., decreased polymorphonuclear leukocyte function,
increased risk of infections, organ damage), it is essential to select patients who need iron
supplementation. Although oral iron administration is the primary treatment for iron defi‐
ciency, it has also disadvantages, such as poor iron absorption and adverse gastrointestinal
reactions, which often lead to poor compliance. Oral iron is ineffective in many CKD pa‐
tients, and parenteral iron administration is required, particularly on those receiving hemo‐
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dialysis [68]. Nevertheless, even with these limitations of oral iron absorption, the cheap
costs of using this route, along with convenience for the patient, often persuade physicians
to try oral iron supplementation first on non-dialysis patients; if, however, there is insuffi‐
cient response after 2 to 3 months, intravenous iron should be administered. However, the
use of IV iron reduces the risk of adverse gastrointestinal reactions and overcomes the prob‐
lem of poor compliance with oral therapy [82, 83]. Another advantage of the i.v. route is that
the iron will not be eliminated by first-pass effects or by high efficiency dialysis membranes
and the iron can be quickly released into the reticuloendothelial system and used for eryth‐
ropoiesis, thus increasing its bioavailability. Intravenous iron administration may not only
decrease hemoglobin variability and ESA hyporesponsiveness, it may also reduce the great‐
er mortality associated with the much higher ESA doses that have been used in some pa‐
tients when targeting higher hemoglobin levels [84]. Other, longer term concerns about
intravenous administration of iron include the potential for increased susceptibility to infec‐
tions and oxidative stress. Much of the scientific evidence for this has been generated in in
vitro experiments, the clinical significance of which is unclear. There is emerging evidence
that intravenous iron may improve the anemia of CKD in up to 30% of patients not receiv‐
ing ESA therapy and have a low ferritin level [85]. Abnormalities of iron metabolism and
anemia in chronic renal failure seem to correlate with levels of serum Hepcidin [86]. Hepci‐
din is a recently discovered protein of expeditious action produced in the liver and that may
play an important role in iron homeostasis [87-89]. Hepcidin limits the absorption of iron
from the intestine and iron release from macrophages and hepatocytes [90]. Iron absorption
capacity in patients with CKD is considerably lower than in non-uremic individuals, partic‐
ularly in the presence of systemic inflammatory activity, and this is probably mediated by
Hepcidin up-regulation [91, 92]. The data in CKD and particularly in ESRD is limited both
in hemodialysis and in peritoneal dialysis [93]. Because of its excretion in the urine [94, 95]
and regulation by the presence or absence of inflammation, it is likely that its metabolism is
affected by renal function and consistently influences the absorption of iron from the intes‐
tine and the stores of iron [96-99]. Originally due to the inability to measure serum levels of
Hepcidin, its role in chronic kidney disease had not been adequately studied and most stud‐
ies involved hepcidin’s levels in urine. It has been attempted to measure prohepcidin a pre‐
cursor peptide of Hepcidin in CKD patients [100, 101]. According to our recently
unpublished data Hepcidin levels were increased in hemodialysis patients in relation to nor‐
mal individuals. The U.S. [16] and European [17] guidelines on renal anemia management
suggest that the ferritin level be maintained in the range of 200 to500 μg/l, with an upper
limit of 800 μg/l. Levels of ferritin above this threshold usually do not confer any clinical ad‐
vantage and may exacerbate iron toxicity. The optimal transferring saturation is above 20%
to 30% to ensure a readily available supply of iron to the bone marrow. Several studies sup‐
port the maintenance of the percentage of hypochromic red cells at levels of less than 6%.
Other measures of iron status, such as serum transferring receptor levels [102] and erythro‐
cyte zinc protoporphyrin levels, are mainly research tools and have not been established in
routine clinical practice. Intramuscular administration of iron is not recommended in CKD,
given the enhanced bleeding tendency, the pain of the injection, and the potential for
brownish discoloration of the skin. Thus, intravenous administration of iron has become the
Hemodialysis320
standard of care for many CKD patients, particularly those receiving hemodialysis [17, 68,
69, 103]. An important advantage of i.v. iron over oral iron is that it may bypass hepcidin
actions by directly loading transferrin and making iron available to macrophages. Despite a
reduction in the short-term risks, there is still concern about the potential for long-term tox‐
icity of i.v. iron use (e. g. atherosclerosis development, infection and increased mortality)
[104, 105] .The association of atherosclerosis with iron overload remains unclear. Alterna‐
tively, the relative risk for mortality or hospitalization from infection in patients undergoing
HD and receiving i.v. iron was shown not to be higher than that observed in the overall HD
population. Indeed, doses of i.v. iron up to 400 mg/month were associated with improved
patient survival. There are several intravenous iron preparations available worldwide, in‐







Dextran Iron* 1000mg 0.0442 (Desired Hb - Observed
Hb) x LBW + (0.26 x  Lean body
weight in kg) (For males: LBW =
50 kg + 2.3 kg for each inch of
patient’s height over 5 feetFor
females: LBW = 45.5 kg + 2.3 kg
for each inch of patient’s height
over 5 feet.)
   A test dose of 25 mg diluted in 50
  ml normal saline and infused over
 5 minutes should be given. Infusion
 should then be stopped for 1 hour.
 If there is no reaction after 1 hour
  continue.
Gluconate Iron* 125mg The recommended dosage of
Sodium Ferric Gluconate for the
repletion treatment of iron
deficiency in hemodialysis
patients is 10 mL of Ferrlecit (125
mg of elemental iron). Ferrlecit
may be diluted in 100 mL of 0.9%
sodium chloride administered by
intravenous infusion over 1 hour
per dialysis session
  No test
Iron Sucrose* 500mg Administer Venofer 100 mg
undiluted as a slow  injection over
2 to 5 minutes, or as an infusion
of 100 mg diluted in a maximum
of 100 mL of 0.9% NaCl over a
period of at least 15 minutes, per
consecutive  session. Venofer
should be administered early
during the dialysis session.
  No test dose
































  1000 mg of iron during a
  minimum administration time of
  </=15 minutes.
  No test dose
Table 1. Avalaible i.v. iron preparations. *: www.globalrph.com - **: www.medicines.org.uk
All of these preparations contain elemental iron surrounded by a carbohydrate shell, which
allows them to be injected intravenously. The liability of iron release from these prepara‐
tions varies, with iron dextran being the most stable, followed by iron sucrose and then iron
gluconate. Iron is released from these compounds to plasma transferrin and other iron-bind‐
ing proteins and is eventually taken up by the reticulo-endothelial system. In hemodialysis
patients, it is easy and practical to give low doses of intravenous iron (e.g., 10 to 20 mg every
dialysis session) or, alternatively, 100 mg weekly. The more stable the iron preparation, the
larger the dose administration rate that can be used. For example, 1gr of iron dextran may
be given by intravenous infusion, whereas the maximum recommended dose of iron sucrose
at any one time is 500 mg. For iron gluconate, doses in excess of 125 to 250 mg are best
avoided. A 100 mg dose of iron sucrose is administered at 10 consecutive HD sessions. If
after the end of the first 10-dose cycle patients remain iron deficient they complete another
10-dose cycle. If TSAT is 20-50% and SF 100-800 ng/mL, the patients start the maintenance
regimen. If TSAT>50% or SF> 800 ng/mL then no further iron supplementation was deemed
necessary. Iron replete patients received the iron maintenance regimen, consisting of 10 one
weekly doses of up to 100 mg iron sucrose over 5 minutes. Iron repletion is defined as TSAT
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20-50% and SF 100-800 ng/mL [106, 107]. Iron sucrose appears to offer the most favorable
safety profile when compared to iron dextran and sodium ferric gluconate in treating hemo‐
dialysis patients. Oxidative stress and hypersensitivity reactions are common problems en‐
countered when administering intravenous iron [108]. Therapy with dextran-free iron
formulations is an essential part of anemia treatment protocols, and was not found to be as‐
sociated with either short- or long-term serious side-effects [109]. Results suggest that 200
mg/FeIV/month is effective and that, of the markers tested, TSAT would be the most suita‐
ble one to the practicing nephrologist so as to optimize intravenous iron in the long run
[110]. Sodium ferric gluconate is well tolerated when given by intravenous push without a
test dose [111]. SFGC has a significantly lower incidence of drug intolerance and life-threat‐
ening events as compared to previous studies using iron dextran. The routine use of iron
dextran in hemodialysis patients should be discontinued [112]. Nevertheless, older i.v. iron
formulations have their limitations, including the potential for immunogenic reactions in‐
duced by dextran molecules (iron dextran) [113], dose limitations, a slow rate of administra‐
tion (to prevent acute, labile iron-induced toxicity and vasoactive reactions) [70, 113] and the
compulsory requirement for a test dose (iron dextrans in USA [114] and Europe. All-event
reporting rates were 29.2, 10.5 and 4.2 reports per million 100 mg iron dose equivalents,
while all-fatal-event reporting rates were 1.4, 0.6 and 0.0 reports per million 100 mg dose
equivalents for iron dextran, sodium ferric gluconate and iron sucrose, respectively [115].
Recently, two new iron preparations have become available for intravenous use (ferumoxy‐
tol in the United States and ferric carboxymaltose in Europe) [116]. Both of these compounds
allow higher doses of intravenous iron to be administered rapidly as a bolus injection, with‐
out the need for a test dose. Ferric carboxymaltose [FCM; FerinjectR; Vifor (International)
Inc., St Gallen, Switzerland] is a next-generation parenteral, dextran-free iron formulation
designed to overcome the limitations of existing i.v. iron preparations. The FCM is a macro‐
molecular ferric hydroxide carbohydrate complex, composed of a poly-nuclear iron(III) hy‐
droxide complexed to carboxymaltose [117]. As FCM is a strong and robust iron complex,
and it can be administered in high doses, it does not release large amounts of reactive (‘free’)
iron into the circulation and does not trigger dextran- associated immunogenic reactions
[111, 117-119]. All intravenous iron preparations carry a risk for immediate reactions, which
may be characterized by hypotension, dizziness, and nausea. These reactions are usually
short-lived and caused by too large a dose given during too short a time. Iron dextran also
carries the risk for acute anaphylactic reactions due to preformed dextran antibodies, and
although this risk may be less with the lower molecular weight iron dextrans, the potential
for anaphylaxis still remains. In such patients, a response to intravenous iron alone may oc‐
cur within 2 to 3 weeks of iron administration. In those already receiving ESAs, there is con‐
siderable evidence that concomitant intravenous iron may enhance the response to the ESAs
and result in lower dose requirements [17, 21, 68]. Ferric carboxymaltose also replenishes
depleted iron stores and improves health-related quality-of-life (HR-QoL) on patients with
iron-deficiency anemia. FCM is at least as effective as iron sucrose and as ferrus sulfate with
regards to end point relative to serum ferritin, transferrin saturation and HR-QoL. Com‐
monly reported drug-related adverse events include headache, dizziness, nausea, abdomi‐
nal pain, constipation, diarrhea, rash and injection-site reactions. The incidence of drug-
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related adverse events on patients receiving intravenous FCM was generally similar to that
in patients receiving oral ferrous sulfate. In general, rash and local injection-site reactions
were more common with ferric carboxymaltose, whereas gastrointestinal adverse events
were more frequent with ferrous sulfate [120]. Based on the No-Observed-Adverse-Effect-
Levels (NOAELs) found in repeated-dose toxicity studies and on the cumulative doses ad‐
ministered, FCM has good safety margins. Lastly, no evidence of irritation was found in
local tolerance studies with FCM [70]. Ferric carboxymaltose may represent a cost-saving
option compared with the most likely alternative existing therapies used for the manage‐
ment of anemia [121, 122].
4.2. Correction of vitamin B and Acid Folic
Vitamin abnormalities in patients with CKD are frequent and appear early even with mild
renal failure; fat-soluble vitamin supplements (A and E) should be avoided and their diet‐
ary intake limited [123]. Deficiency and/or altered metabolism of vitamins in ESRD is caused
by uremic toxins, dietary restrictions, catabolic illness, losses during dialysis and drug in‐
teraction. In patients with polyneuropathy high doses of thiamine pyrophosphate (Cocar‐
boxylase), given i.v., can be helpful in this respect. There are conflicting reports concerning
plasma level  of  vitamin  B2  (riboflavin)  in  ESRD patients.  Some authors  recommend its
supplementation. The majority of patients with ESRD exhibit biochemical and clinical signs
of vitamin B6 deficiency. A univocal opinion exists that supplementation of this vitamin
effects the cellular immune system and the amino acid metabolism as well. An adequate
dose of vitamin B6 is still a matter of dispute. Evidence of vitamin B12 deficiency has been
reported rarely, thus, only few authors recommend the supplementation of it,  mainly in
CAPD patients. According to most authors the losses of folic acid and ascorbic acid dur‐
ing dialysis require oral supplementation. Despite the divergences in opinions concerning
the deficiency of  water-soluble vitamins in ESRD patients,  the supplementation of  these
vitamins is  practiced in many nephrological  centers.  The amount and the route of  vita‐
mins,  administered  to  ESRD  patients,  should  be  individualized  [124-126].  In  ESRD  pa‐
tients  under  maintenance  hemodialysis,  oral  L-carnitine  supplementation  may  reduce
triglyceride and cholesterol and increase HDL and hemoglobin and subsequently reduce
needed erythropoietin dose without effect on QoL [127]. Adjuvant therapy includes: iron,
vitamin C and D, L-carnitine, folic acid, cytokines and growth factors. Vitamin C (500 mg,
after every hemodialysis) is very helpful in cases of functional iron deficiency. L-carnitine
stabilizes the membrane of erythrocytes and prolongs their lives.  Folic acid (10 mg/day)
enhances response to EPO [128]. According to other authors supplementations of pyridox‐
ine in the dose of 20 mg/day and of folic acid 5 mg/week in hemodialyzed patients dur‐
ing erythropoietin treatment are necessary [129].
4.3. Erythropoiesis Stimulating Agents
Erythropoiesis is a complex physiologic process through which homeostasis of oxygen lev‐
els in the body is maintained. It is primarily regulated by EPO, a 30-kD, 165–amino acid
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hematopoietic growth factor that is produced primarily by renal tubular and interstitial
cells. Under normal conditions, endogenous EPO levels change according to O2 tension.
EPO gene expression is induced by hypoxia-inducible transcription factors (HIF) [130]. In
the presence of EPO, bone marrow erythroid precursor cells proliferate and differentiate in‐
to red blood cells. In its absence, these cells undergo apoptosis [131]. Endogenous EPO and
rHuEPO share the same amino acid sequence, with slight but functionally important differ‐
ences in the sugar profile. In clinical practice, rHuEPO is typically administered as a bolus
injection, and the dosage is titrated to give the desired effect [131]. There is no significant
difference between once weekly versus thrice weekly subcutaneous administration of rHu
EPO. Once weekly administration of rHu EPO would require an additional 12U/kg/week for
patients on hemodialysis [132].
Recombinant human erythropoietin has been used for more than 20 years for the treatment
of renal anemia, revolutionizing its treatment in patients with CKD when it was approved
for use in the United States in 1989, [133, 134] with epoetin-alfa and -beta representing the
common traditional preparations. By the modification of the molecule's carbohydrate moi‐
ety or structure a longer duration of erythropoietin receptor stimulation was achieved. The
administration of darbepoetin or C.E.R.A. once or twice a month is also sufficient to achieve
serum hemoglobin target levels, [135] making the treatment safer and more comfortable
both for the patients and the personnel. These synthetic erythropoietin receptor stimulating
molecules, along with recombinant human erythropoietin, are together called "Erythropoie‐
sis Stimulating Agents". The recombinant human erythropoietins and allied proteins (epoe‐
tin-alfa, attempted copies and biosimilar variants of epoetin-alfa, epoetin beta, epoetin delta,
epoetin zeta, epoetin theta, epoetin omega, darbepoetin-alfa, and methoxy-polyethylene gly‐
col-epoetin beta) are among the most successful and earliest examples of biotechnologically
manufactured products to be used in clinical medicine (Table 2) [136].
AVALAIBLE ESAs DOSE REGIMEN
Prototype
epoetin-alfa* Correction phase:
50 IU/kg, 3 times per week.
When a dose adjustment is necessary, this should be done in steps of at
least four weeks. At each step, the increase or reduction in dose should be
of 25 IU/kg, 3 times per week.
Maintenance phase:
Dosage adjustment in order to maintain haemoglobin values at the
desired level: Hb between 10 and 12 g/dl (6.2 - 7.5 mmol/l).
The recommended total weekly dose is between 75 and 300 IU/kg.
epoetin beta* 1. Correction phase
- Subcutaneous administration:
- The initial dosage is 3 x 20 IU/kg body weight per week. The dosage may
be increased every 4 weeks by 3 x 20 IU/kg and week if the increase of Hb
is not adequate (< 0.25 g/dl per week).
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AVALAIBLE ESAs DOSE REGIMEN
- The weekly dose can also be divided into daily doses.
- Intravenous administration:
The initial dosage is 3 x 40 IU/kg per week. The dosage may be raised after
4 weeks to 80 IU/kg three times per week - and by further increments of
20 IU/kg if needed, three times per week, at monthly intervals.
For both routes of administration, the maximum dose should not exceed
720 IU/kg per week.
2. Maintenance phase
To maintain an Hb of between 10 and 12 g/dl, the dosage is initially
reduced to half of the previously administered amount. Subsequently, the
dose is adjusted at intervals of one or two weeks individually for the
patient (maintenance dose).
darbepoetin-alfa* Correction phase:
The initial dose by subcutaneous or intravenous administration is 0.45
µg/kg body weight, as a single injection once weekly.
If the rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in four
weeks reduce the dose by approximately 25%.Dosing should be titrated as
necessary to maintain the haemoglobin target.
If a dose adjustment is required to maintain haemoglobin at the desired
level, it is recommended that the dose is adjusted by approximately 25%
Methoxy-polyethylene
glycol-epoetin beta*
a starting dose of 0.6 microgram/kg bodyweight may be administered
once every two weeks as a single intravenous or subcutaneous injection in
patients on dialysis or not on dialysis. The dose may be increased by
approximately 25% of the previous dose if the rate of rise in haemoglobin
is less than 1.0 g/dl (0.621 mmol/l) over a month. Further increases of
approximately 25% may be made at monthly intervals until the individual
target haemoglobin level is obtained.
Biosimilar
epoetin zeta* 1. Correction phase:
50 IU/kg 3 times per week. When a dose adjustment is necessary, this
should be done in steps of at least four weeks. At each step, the increase
or reduction in dose should be of 25 IU/kg 3 times per week.
2. Maintenance phase:
Dose adjustment in order to maintain haemoglobin (Hb) values at the
desired level: Hb between 10 and 12 g/dl (6.2-7.5 mmol/l). The
recommended total weekly dose is between 75 and 300 IU/kg.
epoetin delta** For Epoetin delta it is recommended to adjust the dose individually to
maintain the target haemoglobin in the range 10 to 12 g/dl. A starting
dose is recommended of 50 IU/kg three times a week if given
intravenously or twice a week if given subcutaneously
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AVALAIBLE ESAs DOSE REGIMEN
epoetin omega*** Starting with 20 to 50 IU / kg three times a week, with a gradual increase
in dose or frequency of issuance before the impact. Beyond hemoglobin
levels to 12 g / m and Hematocrit-35 %. Dose reduction or no treatment. If
there Effect dose increase to 40 to 55 IU / kg three times a week for two
weeks, if necessary, until 60-75 IU / kg The course continues until the level
Hematocrit (35 vol. %) And hemoglobin (12 g / m); Total weekly dose
should not exceed 225 IU / kg supporting-60 IU / kg per week for 2-3
reception
epoetin theta** Correction phase
Subcutaneous administration: The initial posology is 20 IU/kg body weight
3 times per week. The dose may be increased after 4 weeks to 40 IU/kg, 3
times per week, if the increase in haemoglobin is not adequate (< 1 g/dl
[0.62 mmol/l] within 4 weeks). Further increases of 25% of the previous
dose may be made at monthly intervals until the individual target
haemoglobin level is obtained.
Intravenous administration: The initial posology is 40 IU/kg body weight 3
times per week. The dose may be increased after 4 weeks to 80 IU/kg, 3
times per week, and by further increases of 25% of the previous dose at
monthly intervals, if needed.
For both routes of administration, the maximum dose should not exceed
700 IU/kg body weight per week.
Maintenance phase
The dose should be adjusted as necessary to maintain the individual target
haemoglobin level between 10 g/dl (6.21 mmol/l) to 12 g/dl (7.45
mmol/l), whereby a haemoglobin level of 12 g/dl (7.45 mmol/l) should
not be exceeded. If a dose adjustment is required to maintain the desired
haemoglobin level, it is recommended that the dose be adjusted by
approximately 25%. Subcutaneous administration: The weekly dose can
be given as one injection per week or three times per week.
Intravenous administration: Patients who are stable on a three times
weekly dosing regimen may be switched to twice-weekly administration.
If the frequency of administration is changed, haemoglobin level should
be monitored closely and dose adjustments may be necessary.
The maximum dose should not exceed 700 IU/kg body weight per week
Table 2. Available ESAs worldwide. *: ww.medicines.org.uk, **: www.ema.europa.eu, ***: www.pharmabook.net
In hemodialysed patients the intravenous route is preferred, but the subcutaneous admin‐
istration can substantially reduce dose requirements [137-139].  However,  there are stud‐
ies according to which conversion from SC to IV epoetin administration did not result in
changes  in  Hb  levels  or  epoetin  dosage  requirements  in  iron-replete  hemodialysis  pa‐
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tients,  [140]  but  it  seems that  SC route  of  administration was associated with  modestly
higher hemoglobin variability [138].
There are ongoing clinical trials with erythropoiesis stimulating molecules that can be ad‐
ministered by inhalation or per os [137]. It is also known from other studies that some co-
morbidities like antecedents of malignant neoplasm are associated with EPO responsiveness
[141]. In a pre-dialysis population, female gender, cardiovascular disease, malnutrition and
inflammation are associated with ESA hyporesponsiveness [142]. EPO resistance in a pedia‐
tric dialysis cohort was predicted by nutritional deficits, inflammation, poor dialysis, and
hyperparathyroidism, while iron and folic acid deficits were the major determinants in
adults. Although confounded by the pattern of EPO prescription, neither age nor gender
was predictive of EPO resistance in the two study groups [143]. Additionally delivered dial‐
ysis (Kt/ V(urea)) does not seem to be a significant predictor of erythropoietin responsive‐
ness [144]. It also seems that there is difference in EPO hyporesponsiveness prevalence
among different countries and different modalities [145]. The proportion of age has a limited
influence on the level of anemia in pre-dialysis patients and is similar in both genders [146]
There are, although, studies according to which there is higher proportion of anemia in fe‐
male patients [147]. In a multicenter study with 8154 dialysis patients, females, blacks, pa‐
tients between 18 and44 years old on hemodialysis less than six months exhibited
significantly lower mean hemoglobin values despite being prescribed, on average, signifi‐
cantly higher epoetin alfa doses than males, whites and older patients, on hemodialysis
more than six months. A significant regional variation in the prescribing patterns for s.c.
epoetin alfa and i.v. iron has been described in this study [148]. Comparisons between pa‐
tients from western and from eastern/central Europe show that patients from eastern/central
Europe are less likely to receive epoetin treatment before starting dialysis, and have lower
Hb concentrations at the start of epoetin treatment as well as at the start of dialysis [149]. In
another multicenter study by Nissenson et al. there were wide variations in hemoglobin re‐
sponse rate among patients on hemodialysis, hemofiltration and hemodiafiltration [150].
Other factors such as cytokines like IL6 are induced by malignant tumors and may impair
erythropoiesis. Also, TNF-α is known to inhibit this pathway [151]. Low ESA responsive‐
ness was associated with higher mortality in both HD and PD patients [152]. In patients with
persistently low Hb levels, mortality risk is strongly associated with the patient's ability to
achieve a hematopoietic response rather than the magnitude of EPO dose titrations [153]. ESA
dosing may be directly associated with risk of death, but the nature of the association likely
varies according to hemoglobin concentration. Small doses with hemoglobin ≤12 g/dl and large
doses with hemoglobin ≥10 g/dl may both be associated with poor outcomes [154].
Serum albumin concentration is an important predictor of both baseline Hb and EPO sensi‐
tivity in chronic hemodialysis patients. Factors that improve serum albumin may also im‐
prove Hb in hemodialysis patients [155]. Hyperleptinemia reflects better nutritional status
and rHuEPO response in long-term HD patients. Increasing energy intake improves eryth‐
ropoiesis, which may be mediated in part by an increase in serum leptin levels [156, 157].
Statin therapy may improve responsiveness to erythropoietin-stimulating agents in patients
with end-stage renal disease, increasing erythropoiesis by targeting hepcidin and iron regu‐
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latory pathways, independent of erythropoietin [158, 159]. The initial and sustained erythro‐
poietic responses are independent from each other and are associated with different factors.
Treatment focusing on these factors may improve the response [160]. A pleiotropic effect of
EPO has been shown in the kidney, the central nervous system, and the cardiovascular sys‐
tem, [161] such as significant slowing of progression and substantial retardation of mainte‐
nance dialysis [162, 163].
Although ESA use in patients with chronic kidney disease or/and on dialysis were studied
extensively, the optimal target hemoglobin concentration as well as the required ESA dose and
dosing interval to achieve this concentrations remain elusive (NHS, CREATE, CHOIR and
TREAT) [164-167]. Hb can be increased with erythropoiesis-stimulating proteins (ESPs); how‐
ever, 5-10% of patients respond poorly. The patient incidence of hyporesponse seems to be
around 14%, and a mean 9% of patients is hyporesponsive at any given time. The most common
potential causes of hyporesponse is iron deficiency (being reported in 39% of hyporesponse
events), medication (immunosuppressive agents, ACE inhibitors), secondary hyperparathyr‐
oidism [168] and inflammation/malnutrition [169]. The safety profile of epoetin-alfa and dar‐
bepoetin-alfa are similar, but the longer half-life of darbepoetin-alfa permits administration on
a once a week or once-monthly basis in patients with CKD and anemia. Extended dosing of
CERA also appears safe and effective on dialysis patients with CKD [81].
Epoetin alfa: is a recombinant form of erythropoietin, a glycoprotein hormone which stimu‐
lates red blood cell production by stimulating the activity of erythroid progenitor cells. In‐
travenous and subcutaneous therapy with epoetin alfa raises hematocrit and hemoglobin
levels, and reduces transfusion requirements, in anemic patients with end-stage renal failure
undergoing hemodialysis. The drug is also effective in the correction of anemia on patients
with chronic renal failure not yet requiring dialysis and does not appear to affect renal he‐
modynamics adversely or to precipitate the onset of end-stage renal failure. Epoetin alfa
does not appear to exert any direct cerebrovascular adverse effects [170]. Administration of
epoetin alfa at once weekly and fortnightly intervals are potential alternatives to three times
per week dosing for the treatment of anemia [171-173].
Epoetin beta: is a recombinant form of erythropoietin. The drug binds to and activates recep‐
tors on erythroid progenitor cells which then develop into mature erythrocytes. Epoetin beta
increases reticulocyte counts, hemoglobin levels and hematocrit in a dose-proportional man‐
ner. Increases of 15 to 54% in hemoglobin levels and 17 to 60% in hematocrit were reported
after subcutaneous or intravenous epoetin beta therapy in studies of 8 weeks' to 12 months'
duration. Comparative data indicate that dosage reductions of approximately 30% com‐
pared with intravenous therapy are possible when subcutaneous administration of epoetin
beta is used. Hematocrit increased more rapidly in 5 multicenter studies on patients who re‐
ceived epoetin beta subcutaneously than on those who received the same dosage intrave‐
nously. It also causes significant improvements on quality of life, exercise capacity and
overall well-being. Results of clinical studies indicate that subcutaneous administration is
desirable where possible in the majority of patients [174].
Darboepoetin-alfa: It is a hyperglycosylated analog of recombinant human erythropoietin
with the same mechanism of action as erythropoietin, but with a three-fold longer terminal
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half-life after intravenous administration than recombinant human erythropoietin and the
native hormone both in animal models and in humans. It is administered less frequently
(once weekly or every other week) [175, 176]. The recommended starting dose in chronic re‐
nal failure patients is 0.45mcg/kg once weekly for both intravenous and subcutaneous ad‐
ministration, with subsequent titration based on the hemoglobin concentration. The adverse
event profile of darbepoetin-alfa is similar to that of recombinant human erythropoietin in
both settings, [177, 178] and effectively maintains hemoglobin in the target range in dialysis
patients with renal anemia [179]. It also has been shown to be effective when administered
once/week and once every 2, 3, or 4 weeks [180]. There are no reports of antibody formation
associated with darbepoetin-alfa on chronic renal failure patients, and three cases of anti‐
body formation, with neutralizing activity in one of the cases, reported on cancer patients
[181-184].
Cera: Methoxy polyethylene glycol-epoetin beta (MPG-EPO; Mircera®, Roche, Basel, witzer‐
land) is an agent that has a different interaction with the erythropoietin receptor than previ‐
ous agents and has a long elimination half-life (approximately 130 hours) [185]. MPG-EPO is
the only ESA generated by chemical modification of glycosylated erythropoietin, by the in‐
tegration of one specific, long, linear chain of polyethylene glycol. The resultant molecule
has a molecular weight of approximately 60 kDa, which is twice that of epoetin. The me‐
thoxy polyethylene glycol polymer chain is integrated through amide bonds between the N-
terminal amino group or the ε-amino group (predominantly lysine-52 or lysine-45) with a
single butanoic acid linker [186]. In ESA-naïve patients, the recommended starting dose is
0.6 μg/kg administered once every 2 weeks as a subcutaneous or intravenous injection, in
order to reach a hemoglobin level of.11 g/dL. The dose may be increased by approximately
25% if hemoglobin levels increase by, 1.0 g/dL over a month. Further increases of approxi‐
mately 25% may be made once per month until the individual target hemoglobin level is
reached. If a hemoglobin level of.11 g/dL is reached for an individual patient, MPG-EPO
may be continued once per month using a dose equal to twice the previous dose once every
2 weeks. Patients currently being treated with ESA can be directly converted to MPG-EPO
administered once per month as a single intravenous or subcutaneous injection. The starting
dose of this agent is based on the calculated weekly equivalent dose of DA or epoetin at the
time of conversion [187]. The first injection of MPG-EPO should start at the next scheduled
dose of the previously administered DA or epoetin dose. On patients receiving treatment
with ESA and those naïve to ESA, the MPG-EPO dose should be reduced by approximately
25% if the hemoglobin level increases by more than 2 g/dL in 1 month or if the hemoglobin
level approaches 12 g/dL. If hemoglobin levels continue to increase, MPG-EPO administra‐
tion should be interrupted until these levels begin to decrease (a decrease of approximately
0.35 g/dL per week is expected). Therapy should then be resumed at a dose approximately
25% less than the previously administered dose. Dose adjustments should not be made
more frequently than once per month [17, 188]. Once-monthly CERA therapy maintains sta‐
ble Hb values with low intra-individual variability and few dose adaptations in hemodialy‐
sis patients when administered entirely according to local practice, and the regimen is well-
tolerated [189]. C.E.R.A. can be administered to patients at any time during hemodialysis or
hemofiltration without appreciable loss in the extracorporeal circuit [190].
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Peginesatide (formerly known as Hematide™): is a synthetic, peptide-based erythropoiesis-stim‐
ulating agent linked to polyethylene glycol. Based on extensive preclinical and clinical data
substantiating the efficacy and safety of this agent, it was approved in the U.S. in March
2012 for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
Peginesatide (Omontys®) was launched in the U.S. in April 2012 [191, 192]. A drug capable
of stimulating erythropoiesis is the first ESA that bears no structural similarity to rhuEPO.
Peginesatide is a synthetic, dimeric peptide that is covalently linked to polyethylene glycol
(PEG). Peginesatide binds to and activates the human EPO receptor, stimulating the prolif‐
eration and differentiation of human red cell precursors in vitro in a manner similar to ESAs
[193]. Peginesatide administered once monthly was as effective as epoetin alfa given thrice
weekly (dialysis patients) or darbepoetin given once weekly (nondialysis patients), in cor‐
recting anemia of chronic kidney disease as well as maintaining hemoglobin within the de‐
sired target range [194-196].
4.4. Biosimilar
Epoetin zeta:  Epoetin zeta is therapeutically equivalent to epoetin alfa in the maintenance
of  target  Hb levels  on patients  with  renal  anemia.  No unexpected adverse  effects  were
seen [197-201].
Epoetin theta: Has efficacy comparable with epoetin beta (s.c.) in pre-dialysis patients with
renal anemia based on Hb changes from baseline to end of treatment (non-inferiority). The
safety profile was also comparable. Patients could be switched from maintenance treatment
with epoetin beta to epoetin theta without relevant dose changes [202].
Epoetin omega: Epoetin-omega is a sialoglycoprotein with smaller amounts of O-bound sug‐
ars, less acidic and with different hydrophylity than the other 2 epoetins. The initial weekly
dose of epoetin-omega was 90 units per kg of body weight (b.w.) divided in 3 equal portions
and administered subcutaneously after each dialysis session. After correction of the hemoglo‐
bin, the dose of rHuEPO was individualized to keep Hb within target limits of 100-120 g/l. The
mean dose of epoetin-omega during the correction period never exceeded 100 U/kg b.w. per
week and the average maintenance dose between 50-60 U/kg b.w. per week [203, 204].
HX575: Is a biosimilar version of epoetin-α that is approved for the treatment of anemia as‐
sociated with chronic kidney disease (CKD) using the intravenous route of administration
[205, 206]. In a study for S.C. use two patients developed neutralizing antibodies (NAbs) to
erythropoietin, which resulted in the study being terminated prematurely [207].
4.5. Adverse effects of EPO therapy
Adverse effects of EPO therapy are uncommon, apart from a moderate increase in blood pressure
and an increased rate of vascular access thrombosis. In spite of the fact that, these effects are
probably dependent to a large degree on the increase in Hb concentrations, there are some
concerns that ESA therapy may enhance thrombogenicity and tumor growth on patients with
malignant disease as well as exacerbate vascular events in CKD independently of Hb concen‐
trations [208]. In treatment with epoetin alfa hypertension occurs in 30 to 35% of patients with
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end-stage renal failure, but this can be managed successfully with correction of fluid status
and antihypertensive medication where necessary, and is minimized by avoiding rapid in‐
creases in hematocrit. Although vascular access thrombosis has not been conclusively linked
to therapy with the drug, increased heparinisation may be required when it is administered to
patients on hemodialysis [170]. On patients who receive epoetin beta, hypertension may occur
but may be minimized by avoiding rapid increases in hematocrit (> 0.5%/week), and is man‐
aged in most cases with control of fluid status and antihypertensive medication. Although
clotting of the vascular access has not been conclusively linked to epoetin beta, caution is
recommended on patients undergoing hemodialysis. Increased heparinisation is recommend‐
ed to prevent clotting in dialysis equipment [174]. Before 1998, EPO alfa in Europe was formulated
with human serum albumin, but because of a change in European regulations, this was replaced
with polysorbate 80. EPO beta is formulated with polysorbate 20, along with urea, calcium
chloride, and five amino acids as excipients. The importance of the formulation of the EPO
products was highlighted in 2002 with an upsurge in cases of antibody-mediated pure red cell
aplasia in association with the subcutaneous use of EPO alfa after its change for indicate
mulation. Patients affected by this complication develop neutralizing antibodies against both
rhuEPO and the endogenous hormone, which result in severe anemia and transfusion depend‐
ence [209, 210]. The cause of this serious complication in which there is a break in B-cell tolerance
remains obscure, although it seems likely that factors such as a breach of the cold storage chain
were relevant,  and the subcutaneous application route was a prerequisite;  circumstantial
evidence also suggested that rubber stoppers of prefilled syringes used in one of the albumin-
free EPO alfa formulations may have released organic compounds that acted as immunolog‐
ic adjuvants [211].
4.6. Which target is the best for the correction of anemia on hemodialysis patients?
There has been considerable debate in recent times about the optimal target range of Hb in
CKD patients [133]. The improvement in quality of life with increasing Hb concentrations
supports a level above 10 to 11 g/dl in all CKD patients, [16, 17] but some studies have indi‐
cated increased risks associated with attempts to completely correct anemia. No survival
benefit is evident at a higher level of anemia correction, [13, 164, 165, 167] although quality
of life and exercise capacity may be greater. Thus, there is a possible tradeoff between im‐
proved quality of life and increased cost and risk for harm, so that a target level of Hb above
13 g/dl should be avoided [16]. Clinical trials of erythropoiesis-stimulating agents indicate
that targeting the complete correction of anemia in patients with chronic kidney disease re‐
sults in a greater risk of morbidity and mortality despite improved hemoglobin and quality
of life [59, 164, 212]. Although there are studies that state the opposite [213, 214]. Relation‐
ships between hemoglobin concentration and mortality differed between African Americans
and whites. Additionally, the relationship of lower mortality with greater achieved hemo‐
globin concentration seen in white patients was observed for all-cause, but not cardiovascu‐
lar mortality [215]. Erythropoiesis-stimulating agents should be used to target hemoglobin
11-12 g/dl on patients with chronic kidney disease. However, a risk-benefit evaluation is
warranted in individual patients, and high ESA doses driven by hyporesponsiveness should
be avoided [216]. Intravenous iron may be beneficial for patients with hemoglobin less than
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11 g/dl and transferrin saturation less than 25% despite elevated ferritin (500-1200 ng/ml)
[217, 218]. TREAT and other large randomized, controlled trials of ESA treatment on pa‐
tients with CKD have not demonstrated a clinical benefit in terms of mortality, morbidity, or
quality of life improvement of targeting Hb levels greater than 12-13 g/dl. Some of these
studies have demonstrated increased risk of stroke, vascular access thrombosis, hyperten‐
sion, and other events [219]. The European Renal Best Practice (ERBP), which are issued by
ERA-EDTA, are suggestions for clinical practice in areas in which evidence is lacking or
weak, together with position statements on published randomized controlled trials, or on
existing guidelines and recommendations. In 2009, the Anemia Working Group of ERBP
published its first position statement about the hemoglobin target to aim for with erythro‐
poietin-stimulating agents (ESA) and on issues that were not covered by K-DOQI in 2006-07.
Following the findings of the TREAT study, the Anemia Working Group of ERBP maintains
its view that 'Hb values of 11-12 g/dL should be generally sought in the CKD population
without intentionally exceeding 13 g/dL and that the doses of ESA therapy to achieve the
target hemoglobin should also be considered. More caution is suggested when treating ane‐
mia with ESA therapy on patients with type 2 diabetes not undergoing dialysis (and proba‐
bly in diabetics at all CKD stages). To those with ischemic heart disease or with a previous
history of stroke, possible benefits should be weighed up against an increased risk of stroke
recurrence, when deciding which Hb level to aim for. These recommendations are not in‐
tended to represent a new guideline as they are not the result of a systematic review of evi‐
dence [220]. The National Kidney Foundation (NKF) and the Food and Drug Administration
(FDA) recommend different target levels for hemoglobin in patients with terminal kidney
disease treated by hemodialysis [79, 221]. The NKF recognizes also the importance of indi‐
vidualizing the treatment of anemia. The optimal range of target hemoglobin levels in Kainz
et al analysis of hemodialysis patients was 11 g/day. Furthermore, ESA hypo-responders
showed an increased risk of mortality with higher hemoglobin levels, and ESA responders
actually exhibited a decreased risk [222]. A corrected weekly ESA dose up to 16 000 units
with achieved hemoglobin levels ~11 g/dL exhibited the lowest mortality risk. Hemoglobin
variability as well as ESA hypo-response causing low hemoglobin levels was associated
with a numerically increased risk of mortality compared with patients with stable hemoglo‐
bin levels between 10 and 12 g/dL. Furthermore, ESA response requiring more than 16 000
units per week was also associated with an increased risk of death in ESA responders [222].
The Japanese Society for Dialysis Therapy (JSDT) guideline committee presents the Japanese
guidelines entitled "Guidelines for Renal Anemia in Chronic Kidney Disease." These guide‐
lines replace the "2004 JSDT Guidelines for Renal Anemia in Chronic Hemodialysis Pa‐
tients," and contain new, additional guidelines for peritoneal dialysis (PD), non-dialysis
(ND), and pediatric CKD patients [223]. Values for diagnosing anemia are based on the most
recent epidemiological data from the general Japanese population. To both men and wom‐
en, Hb levels decrease along with an increase in age and the level for diagnosing anemia has
been set at <13.5 g/dL on males and <11.5 g/dL on females. Renal anemia is identified as an
"endocrine disease." It is believed that in this way defining renal anemia will be extremely
beneficial for ND patients exhibiting renal anemia despite having a high GFR. We have also
emphasized that renal anemia may not only be treated with ESA therapy but also with ap‐
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propriate iron supplementation and the improvement of anemia associated with chronic
disease, which is associated with inflammation, and inadequate dialysis, another major
cause of renal anemia. In Japanese HD patients, Hb levels following hemodialysis rise con‐
siderably above their previous levels because of ultrafiltration-induced hemoconcentration;
and (ii) as noted in the 2004 guidelines, although 10 to 11 g/dL was optimal for long-term
prognosis if the Hb level prior to the hemodialysis session in an HD patient had been estab‐
lished at the target level, it has been reported that, based on data accumulated on Japanese
PD and ND patients, higher levels have a cardiac or renal function protective effect, on pa‐
tients without serious cardiovascular disease,without any safety issues.. Accordingly, the
guidelines establish a target Hb level in PD and ND patients of 11 g/dL or more, and recom‐
mend 13 g/dL as the criterion for dose reduction/withdrawal. If the serum ferritin is <100
ng/mL and the transferrin saturation rate (TSAT) is <20%, then the criteria for iron supple‐
mentation will be met; if only one of these criteria is met, then iron supplementation should
be considered unnecessary [223]. Italian Society of Nephrology in its guidelines for the treat‐
ment of anemia in chronic renal failure supports that before beginning epoetin treatment, it
is essential to evaluate the level of anemia by the measuring Hb concentration, Red blood
cell indices (MCV, MCH, MCHC), Reticulocyte count, Iron stores and availability and C-re‐
active protein (CRP). The minimum target Hb concentration to be attained is 11 g/dL. The
upper limit is established individually on a clinical basis. Pending further data, it is advisa‐
ble to maintain and not exceed 12 g/dL for patients with cardiovascular disease, diabetes,
and graft access. In the presence of adequate reserves of iron the need for higher dosages of
epoetin define a state of resistance [224].
Iron deficiency (60%) measured by ferritin levels and TSAT at start of dialysis was found in
Predialysis Survey on Anemia Management (21 European countries, Israel and South Afri‐
ca) despite the majority of patients under nephrologist’s care for more than twelve months.
Only 27% of patients had started epoetin treatment before dialysis therapy. Thirteen percent
had started dialysis therapy first, 33% had started epoetin and dialysis therapy simultane‐
ously, and 28% had not been administered epoetin at any time (total n = 4,095).
[225] Difference in hemoglobin levels was found in DOPPS study and mean Hgb levels were
12 g/dL in Sweden; 11.6 to 11.7 g/dL in the United States, Spain, Belgium, and Canada; 11.1 to
11.5 g/dL in Australia/New Zealand, Germany, Italy, the United Kingdom, and France; and
10.1 g/dL in Japan. Hgb levels were substantially lower for new patients with end-stage renal
disease, and EPO use before ESRD ranged from 27% (United States) to 65% (Sweden) [21].
At present, there is a "grey zone" also between the intervention threshold of Hb< 9 g/dl and
an Hb level > 13 g/dl, at which CKD is associated with a higher risk of cardiovascular
events. It seems to be clearly evident that ESA activate platelets directly and indirectly, and
that pathologically extended bleeding time is normalized when an Hb level of 10 g/dl is
reached; from the hemostaseological perspective, a threshold level for treatment of renal
anemia with ESA is thus defined. According to the present state of knowledge, an Hb target
range of 10-11 g/dl seems reasonable for renal anemia; this is also compatible with current
recommendations by ESA producers and the Food and Drug Administration (FDA) [226].
This target range avoids the upper and lower risk levels for Hb, and probably ensures a pos‐
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itive ESA effect on quality of life; it is much more cost-efficient than the target range of 11-12
g/dl recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) in 2007
[227]. ESA treatment for renal anemia should be aimed at reducing transfusion risk, with a
treatment target in most patients of 10-12 g/dl; therapy should be individualized, rapid in‐
creases in Hb level should probably be avoided, and lowest appropriate ESA doses should
be used. Temptation to increase ESA doses to very high levels in an attempt to overcome
ESA hypo responsiveness should be resisted [219]. It seems that greater hemoglobin varia‐
bility is independently associated with higher mortality [228]. Variability caused by labora‐
tory assays, biological factors, and therapeutic response determines patient Hb level
variability. Improving factors that can be manipulated (e.g., standardizing EPO and iron al‐
gorithms) and adjustment of the target Hb level range, specifically, by increasing the upper
bound, likely will decrease the observed variability and further enhance the quality of ane‐
mia management [229, 230].
5. Conclusion
It is obvious that renal anemia in hemodialysis patients remain a serious problem. This was
greater before EPO era, when blood transfusion was the only therapeutic approach. Insuffi‐
ciency of iron and EPO are the most important causes of this anemia. Nowadays with the
availability of new I.V. iron supplementation and ESAs this problem became more managea‐
ble. The high cost of the EPO treatment makes the iron therapy essential in order to maxi‐
mize EPO administration result with the lower dose. The ideal hemoglobin target has to be
established despite the numerous trials worldwide, and the treatment has to be individualized.
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